肠道益生菌在制备促进鞣花酸代谢为尿石素A的药物中的应用及其药物组合物和应用
By optimizing the combination of intestinal probiotics and ellagic acid, the structure of the intestinal flora is changed, which solves the problem of insufficient ellagic acid metabolism in people with type O and type B, and realizes the high-yield application of urolithin A, which has the potential to treat a variety of diseases.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG UNIV
- Filing Date
- 2023-05-19
- Publication Date
- 2026-07-17
AI Technical Summary
In the existing technology, people with type O and type B cannot effectively metabolize ellagic acid into urolithin A, which limits its application in these populations. Furthermore, existing methods for improving gut microbiota have failed to significantly increase the yield of urolithin A.
By screening and optimizing the combination of various intestinal probiotics, such as Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium breve, a specific ratio of probiotic flora is formed. Ellagic acid is then added to change the intestinal flora structure to promote the metabolism of ellagic acid into urolithin A.
It significantly increased the production of urolithin A in people with blood type O and B, providing a new approach to treat diseases such as diabetes, obesity, aging, and central nervous system disorders.
Smart Images
Figure CN116376783B_ABST